Cara Therapeutics (CARA)
(Delayed Data from NSDQ)
$0.27 USD
0.00 (0.68%)
Updated Oct 17, 2024 03:59 PM ET
After-Market: $0.26 -0.01 (-2.55%) 7:46 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.27 USD
0.00 (0.68%)
Updated Oct 17, 2024 03:59 PM ET
After-Market: $0.26 -0.01 (-2.55%) 7:46 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Zacks News
Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study
by Zacks Equity Research
Kodiak Sciences (KOD) completes recruitment in the pivotal phase IIb/III DAZZLE study, currently evaluating KSI-301 for the treatment of patients with wet age-related macular degeneration.
Roche's (RHHBY) Influenza Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Roche's (RHHBY) influenza drug Xofluza and Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) get a positive CHMP opinion.
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 48.53% and 86.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Cara (CARA) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Cara (CARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 20.59% and 2.90%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Cara Therapeutics (CARA) Stock a Solid Choice Right Now?
by Zacks Equity Research
Cara Therapeutics (CARA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 1.59% and 67.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cara Therapeutics (CARA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cara Therapeutics.
Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 1.61% and -19.13%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -25.42% and 4.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 4.92% and 1.38%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cara Shares Up on Positive Phase III Data for Itchiness Drug
by Zacks Equity Research
Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.
Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -1.82% and -14.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 11.86% and 65.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
Is a Beat in Store for Catabasis (CATB) This Earnings Season?
by Zacks Equity Research
Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.
Can Segmental Growth Aid Cooper Companies' (COO) Q1 Earnings?
by Zacks Equity Research
Management at Cooper Companies (COO) expects solid contributions from CVI and CSI units.
What's in Store for Vericel (VCEL) This Earnings Season?
by Zacks Equity Research
On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.
Cara (CARA) Up on IDMC's Recommendation to Continue Trial
by Zacks Equity Research
Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.